As a test for positive predictive capability, we chose the same GATA-3 (CGUC)27 and c-jun (CGUU)28 cut sites previously evaluated in clinical trials as treatments for allergic asthma and nodular basal-cell carcinoma, respectively. The gene discussed is GATA3; the disease is basal cell carcinoma.